Efficacy and safety of four-weeks versus twelve-weeks loading doses spacing of intravitreal Aflibercept for treatment of macular edema associated with Central Retinal Vein Occlusio
Not Applicable
Not yet recruiting
- Conditions
- Eye Diseases
- Registration Number
- PACTR202201655513401
- Lead Sponsor
- Egypt health insurance
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Any participant to be included in the study should have:
normal or controlled blood pressure.
normal Hba1c or controlled (maximum 6.5%).
normal or controlled lipogram.
Patients aged =18 years with center-involved macular edema due to CRVO (CMT =250 µm on OCT).
Best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 to 24 letters)
Exclusion Criteria
Exclusion criteria comprised the following:
pregnancy or lactation.
glaucoma.
cataract.
previous vitreoretinal or filtration surgery.
iris neovascularization.
any systemic or ocular disorder in the study eye that may confound the interpretation of the study results.
previous treatment with any anti-VEGF agents.
systemic anti-angiogenic medications.
intraocular corticosteroids
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Best corrected visual acuity changes at follow up time points.
- Secondary Outcome Measures
Name Time Method Changes in central macular thickness and choroidal thickness as measured by OCT.<br>Reporting any ocular or systemic complications related to intravitreal injection of Aflibercept.<br>